Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mystem Biotechnologies Inc. is handling 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to a distinct examiner, GU, QINHUA, who is the busiest examiner for the company. The prosecution is currently limited to 1 distinct art unit.
This profile reflects a highly focused and singular engagement with the patent office. The concentration in one art unit and one examiner means the company's immediate success in this technology area depends entirely on the outcome of this specific interaction. Practitioners should note that there is no diversification across examiners or art units for the current pending workload.
This lack of breadth means that the specific preferences of the assigned examiner will be the primary factor in the prosecution outcome. The company's strategy appears to be highly targeted within the technical group identified. This concentrated approach requires a direct and focused interaction with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GU, QINHUA | 1 | 76.2% | +27.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19071220 | Colostrum Derived Stem Cells, Neural Differentiation, Compositions and Supplements for Enhancing Mammalian Health | GU, QINHUA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19071220 | Colostrum Derived Stem Cells, Neural Differentiation, Compositions and Supplements for Enhancing Mammalian Health | GU, QINHUA | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19071220 | Colostrum Derived Stem Cells, Neural Differentiation, Compositions and Supplements for Enhancing Mammalian Health | GU, QINHUA | 1633 | §103§112 | Non-Final OA | — | Pending | Mar 05, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMystem Biotechnologies Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Qinhua Gu has the most, with 1 of Mystem Biotechnologies Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
